«The most common use of artificial intelligence in biopharmaceutical research and development over the past few years was drug discovery, according to a report out today from IQVIA. The report identified 19 clinical trials between 2018 and 2022 in which artificial intelligence and machine learning played a role in the research stage. While it’s still early days, it’s expected these technologies will help speed up drug development. More than half of the trials used AI to analyze complex datasets to optimize drug design. Other uses included identifying “druggable” targets, precision patient targeting and trial simulation. “The expectation is that trials using [artificial intelligence and machine learning] will deliver faster results at lower risk based on optimized drug characteristics and trial execution,” the report noted.»

Article written by Harietta Eleftherochorinou / Photo by Francisco Venâncio (unsplash)